(Q38050686)

English

Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1.

scientific article published on 10 October 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1. (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

drug interaction

0 references

Constanze Hilgendorf

object named as

C Hilgendorf

2

0 references

author name string

R Elsby

1

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

K Fenner

3

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

language of work or name

0 references

publication date

10 October 2012

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Clinical Pharmacology & Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

92

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

584-598

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

The search beyond statins

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Weighing the benefits of high-dose simvastatin against the risk of myopathy.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Statin-induced myopathy: a review and update

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins).

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Role of OATP transporters in the disposition of drugs

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Transporter pharmacogenetics and statin toxicity

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Relationship between drug/metabolite exposure and impairment of excretory transport function.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Transporter-mediated drug--drug interactions involving OATP substrates: predictions based on in vitro inhibition studies.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

SLCO1B1 variants and statin-induced myopathy--a genomewide study

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

The SLCO1B1*5 genetic variant is associated with statin-induced side effects

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Pharmacokinetics of the CYP 3A substrate simvastatin following administration of delayed versus immediate release oral dosage forms

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Simvastatin: a review

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Prediction of the in vivo OATP1B1-mediated drug-drug interaction potential of an investigational drug against a range of statins

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Clinical Pharmacokinetics of Atorvastatin

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Kinetic characterization of rat hepatic uptake of 16 actively transported drugs

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Clinical pharmacokinetics of fluvastatin

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Pitavastatin: an overview

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Drug-drug interaction between pitavastatin and various drugs via OATP1B1.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

The effect of fluconazole on the pharmacokinetics of rosuvastatin

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Peptide prodrugs: improved oral absorption of lopinavir, a HIV protease inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Mechanism-based inactivation of CYP3A by HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Role of itraconazole metabolites in CYP3A4 inhibition

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Poor solubility limiting significance of in-vitro studies with HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

21 January 2018

Use of transporter knockdown Caco-2 cells to investigate the in vitro efflux of statin drugs

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

7 January 2021

based on heuristic

inferred from DOI database lookup

Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

7 January 2021

based on heuristic

inferred from DOI database lookup

Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

7 January 2021

based on heuristic

inferred from DOI database lookup

Urolithiasis in HIV-positive patients treated with atazanavir

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.163

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/CLPT.2012.163

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38050686&oldid=2122976804"